In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The decision is based on the phase 3 DESTINY-Breast11 trial
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Subscribe To Our Newsletter & Stay Updated
